Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

Vrooman et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d8e82833ca018b39ae44eb — DOI: https://doi.org/10.1200/jco.20.03692

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial· 2015 · 237 citations
2. <i>Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001</i>· 2020 · 3 citations
3. Comparative pharmacokinetic studies of three asparaginase preparations.· 1993 · 336 citations
4. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01· 2001 · 869 citations
5. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group· 2020 · 183 citations